List of Parsabiv drug patents
Parsabiv is owned by Kai Pharms Inc.
Parsabiv contains Etelcalcetide.
Parsabiv has a total of 7 drug patents out of which 0 drug patents have expired.
Parsabiv was authorised for market use on 07 February, 2017.
Parsabiv is available in solution;intravenous dosage forms.
Parsabiv can be used as a method of treating secondary hyperparathyroidism (shpt).
Drug patent challenges can be filed against Parsabiv from 2021-02-07.
The generics of Parsabiv are possible to be released after 27 June, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(7 years from now) | |
| US8999932 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Feb, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 2021-02-07
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION;INTRAVENOUS
PARSABIV family patents
21
United States
7
European Union
4
China
4
Japan
4
Lithuania
4
Hungary
3
Spain
3
Denmark
3
Poland
3
Singapore
3
Croatia
3
Portugal
3
Slovenia
2
Hong Kong
2
Brazil
2
Canada
2
New Zealand
2
Korea, Republic of
2
Cyprus
2
Peru
2
Israel
2
Taiwan
2
Mexico
2
Australia
2
Costa Rica
2
South Africa
1
Uruguay
1
Philippines
1
Malaysia
1
Turkey
1
RS
1
Russia
1
Ukraine
1
Morocco
1
Argentina
1
EA
1
Norway
1
ME
1
San Marino
1
Chile
1
Jordan
1
Luxembourg
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic